The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
Open accessAbstract
Purpose: Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit. Preclinical and clinical studies support VEGFR and PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role of pazopanib maintenance therapy in patients with ovarian cancer whose disease did not progress during first-line chemotherapy. Patients and Methods: Nine hundred forty patients with histologically confirmed cancer of the ovary, fallopian tube, or peritoneum, International Federation Gynecology Obstetrics (FIGO) stages II-IV, no evidence of progression after primary therapy consisting of surgery and at least five cycles of platinum-taxane chemotherapy were randomized 1:1 to receive pazopanib 800 mg once per day or placebo for up to 24 months. The primary end point was progression-free survival by RECIST 1.0 assessed by the investigators. Results: Maintenance pazopanib prolonged progression-free survival compared with placebo (hazard ratio [HR], 0.77; 95% CI, 0.64 to 0.91; P = .0021; median, 17.9 v 12.3 months, respectively). Interim survival analysis based on events in 35.6% of the population did not show any significant difference. Grade 3 or 4 adverse events of hypertension (30.8%), neutropenia (9.9%), liver-related toxicity (9.4%), diarrhea (8.2%), fatigue (2.7%), thrombocytopenia (2.5%), and palmar-plantar erythrodysesthesia (1.9%) were significantly higher in the pazopanib arm. Treatment discontinuation related to adverse events was higher among patients treated with pazopanib (33.3%) compared with placebo (5.6%). Conclusion: Pazopanib maintenance therapy provided a median improvement of 5.6 months (HR, 0.77) in progression-free survival in patients with advanced ovarian cancer who have not progressed after first-line chemotherapy. Overall survival data to this point did not suggest any benefit. Additional analysis should help to identify subgroups of patients in whom improved efficacy may balance toxicity (NCT00866697).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Survival Analysis, Techniques for Censored and Truncated Data
Rao, M. B. (1998) · Technometrics · doi:10.1080/00401706.1998.10485206 · Cited by 3,617
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Self-citationCannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Survival Analysis: Techniques for Censored and Truncated Data
Klein, J. P., & Moeschberger, M. L. (2003) · Statistics for Biology and Health · doi:10.1007/b97377 · Cited by 1,816
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Self-citationMallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Vascular Endothelial Growth Factor
Ferrara, N. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179663 · Cited by 1,283
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
Self-citationRatain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,032
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Self-citationGenetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 807
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis
Gao, D., Nolan, D. J., Mellick, A. S., Bambino, K., McDonnell, K., & Mittal, V. (2008) · Science · doi:10.1126/science.1150224 · Cited by 632
Rustin, G. J. S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G., Jakobsen, A., Sagae, S., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182070f17 · Cited by 625
Self-citationDrazen, J. M., Yandava, C. N., Dubé, L., Szczerback, N., Hippensteel, R., Pillari, A., Israel, E., Schork, N., Silverman, E. S., Katz, D. A., et al. (1999) · Nature Genetics · doi:10.1038/9680 · Cited by 560
du Bois, A., Quinn, M., Thigpen, T., Vermorken, J., Avall-Lundqvist, E., Bookman, M., Bowtell, D., Brady, M., Casado, A., Cervantes, A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi961 · Cited by 465
Self-citationMarkman, M., Liu, P. Y., Wilczynski, S., Monk, B., Copeland, L. J., Alvarez, R. D., Jiang, C., & Alberts, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.013 · Cited by 447
Self-citationThe use of single-nucleotide polymorphism maps in pharmacogenomics
McCarthy, J. J., & Hilfiker, R. (2000) · Nature Biotechnology · doi:10.1038/75360 · Cited by 434
Role of Vascular Endothelial Growth Factor in Ovarian Cancer
Mesiano, S., Ferrara, N., & Jaffe, R. B. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65669-6 · Cited by 392
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
Rustin, G. J. S., Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., Greven, K., Vergote, I., et al. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh081 · Cited by 378
Self-citationMinireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Romero, I., & Bast, R. C. (2012) · Endocrinology · doi:10.1210/en.2011-2123 · Cited by 286
Health Utilities Using the EQ-5D in Studies of Cancer
Pickard, A. S., Wilke, C. T., Lin, H.-W., & Lloyd, A. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725050-00002 · Cited by 285
Schueneman, A. J., Himmelfarb, E. A., Geng, L., Tan, J., Donnelly, E. F., Mendel, D. B., McMahon, G., & Hallahan, D. E. (2003) · PubMed · Cited by 259
Abrams, T. J., Murray, L. J., Pesenti, E. A., et al. (2003) · PubMed · Cited by 251
Watson, R. T. (2001) · Cited by 250
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2012) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3182547170 · Cited by 244
Self-citationA Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Friedlander, M., Hancock, K. C., Rischin, D., Messing, M. J., Stringer, C. A., Matthys, G. M., Ma, B., Hodge, J. P., & Lager, J. J. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.033 · Cited by 226
Self-citationThe epidemiology of ovarian cancer
Parazzini, F., Franceschi, S., La Vecchia, C., & Fasoli, M. (1991) · Gynecologic Oncology · doi:10.1016/0090-8258(91)90003-n · Cited by 212
Pfisterer, J., Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., Bourgeois, H., Meier, W., Costa, S., Blohmer, J.-U., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj296 · Cited by 211
Self-citationdu Bois, A., Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J.-C., Kuhn, W., Orfeuvre, H., Wagner, U., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2938 · Cited by 196
Self-citationVerheijen, R. H., Massuger, L. F., Benigno, B. B., Epenetos, A. A., Lopes, A., Soper, J. T., Markowska, J., Vyzula, R., Jobling, T., Stamp, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5973 · Cited by 193
Herzog, T. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0683 · Cited by 188
Self-citationOregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
Berek, J., Taylor, P., McGuire, W., Smith, L. M., Schultes, B., & Nicodemus, C. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8400 · Cited by 172
Genome-based pharmacogenetics and the pharmaceutical industry
Roses, A. D. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd840 · Cited by 168
Hirte, H. W., Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B. E., Tu, D., Sadura, A., Brundage, M., & Seymour, L. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.020 · Cited by 152
Self-citationSabbatini, P. J., Harter, P., Scambia, G., Sehouli, J., Meier, W., Wimberger, P., Baumann, K., Kurzeder, C., Schmalfeldt, B., Cibula, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4057 · Cited by 145
Self-citationUse of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer
Rustin, G. J. S., Bast, R. C., Kelloff, G. J., Barrett, J. C., Carter, S. K., Nisen, P. D., Sigman, C. C., Parkinson, D. R., & Ruddon, R. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0787 · Cited by 133
Peeters, C. F. J. M., de Waal, R. M. W., Wobbes, T., Westphal, J. R., & Ruers, T. J. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21928 · Cited by 127
Vergote, I. B., Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., Marth, C., Hall, M., Steer, C., Colombo, N., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5669 · Cited by 121
Self-citationRustin, G. J. S., Timmers, P. J., Nelstrop, A. E., Shreeves, G., Bentzen, S. M., Baron, B., Piccart, M. J., Bertelsen, K., Stuart, G. C. E., Cassidy, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.2757 · Cited by 102
Maintenance chemotherapy for ovarian cancer
Mei, L., Chen, H., Wei, D. M., Fang, F., Liu, G. J., Xie, H. Y., Wang, X., Zhou, J., & Feng, D. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007414.pub3 · Cited by 95
Dual Targeting of Endothelial Cells and Pericytes in Antivascular Therapy for Ovarian Carcinoma
Lü, C., Kamat, A. A., Lin, Y. G., Merritt, W. M., Landen, C. N., Kim, T. J., Spannuth, W. A., Arumugam, T., Han, L. Y., Jennings, N. B., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0197 · Cited by 90
First-Line Therapy in Ovarian Cancer Trials
Thigpen, T., duBois, A., McAlpine, J. N., DiSaia, P. J., Fujiwara, K., Hoskins, W. J., Kristensen, G. B., Mannel, R. S., Markman, M. M., Pfisterer, J., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821ce75d · Cited by 85
Self-citationTesting drug response in the presence of genetic information: sampling issues for clinical trials
Cardon, L. R., Idury, R. M., Harris, T., Witte, J. S., & Elston, R. C. (2000) · Pharmacogenetics · doi:10.1097/00008571-200008000-00003 · Cited by 75
Metastatic Dormancy Imposed by the Primary Tumor: Does it Exist in Humans?
Peeters, C. F. J. M., de Waal, R. M. W., Wobbes, T., & Ruers, T. J. M. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0029-5 · Cited by 63
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer
Lü, C., Thaker, P. H., Lin, Y. G., Spannuth, W. A., Landen, C. N., Merritt, W. M., Jennings, N. B., Langley, R. R., Gershenson, D. M., Yancopoulos, G. D., et al. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.12.028 · Cited by 62
A comparison of two simple hazard ratio estimators based on the logrank test
Berry, G., Kitchin, R., & Mock, P. A. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100510 · Cited by 60
Using single nucleotide polymorphisms as a means to understanding the pathophysiology of asthma
Palmer, L. J., & Cookson, W. (2001) · Respiratory Research · doi:10.1186/rr45 · Cited by 59
Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop☆
Bast, R. C., Thigpen, J. T., Arbuck, S. G., Basen‐Engquist, K., Burke, L. B., Freedman, R. S., Horning, S. J., Ozols, R. F., Rustin, G. J. S., & Spriggs, D. R. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.092 · Cited by 58
Pazopanib, a new therapy for metastatic soft tissue sarcoma
Verweij, J., & Sleijfer, S. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.780030 · Cited by 52
Ghamande, S. A., Silverman, M. H., Huh, W. K., Behbakht, K., Ball, G., Cuasay, L. C., Würtz, S. Ø., Brünner, N., & Gold, M. A. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.06.028 · Cited by 49
Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
Monk, B. J., Dalton, H., Farley, J. H., Chase, D. M., & Benjamin, I. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.09.012 · Cited by 46
Self-citationA comparison of two simple hazard ratio estimators based on the logrank test
Sato, T. S., & Berry, G. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110614 · Cited by 44
Venterea, R. T., Parkin, T. B., Cardenas, L., Petersen, S., & Pedersen, A. R. (2012) · Rothamsted Repository (Rothamsted Repository) · Cited by 27
Cited by
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Treatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z.-H., & Telleria, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 680
Advances in ovarian cancer therapy
Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3501-8 · Cited by 624
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
Self-citation
Metadata
- Authors
- du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M.-A., Kim, J.-H., Kurzeder, C., Lesoin, A., Vasey, P., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B.-G., Herzog, T. J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R., & Harter, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-10-20
- Volume
- 32
- Issue
- 30
- Pages
- 3374-3382
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133537644
- Cited by
- 328
- References
- 64
- FWCI
- 45.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.